Couple of them are cell and Gene so out of the equation (e.g. MSB)...and some are looking at Oncology which always attracts premium....
However point taken that not all are in the MC I mentioned.....Some of back up my points were ACW, EX1, DKB (haha I own it, a big disappointment this year but heck I bought super low so still positive).etc....And someone said it failed P2, its not the case....problem with DXB is not science but horrible management...(they have bloody 3 P3 studies next year and still this MC..phew)
I think I was replying to one of the posts expecting a 100% increase on back of yearterday ann. for vivo trials which I said was a dream wish...And so it turned out to be the case....
Bottom line is there are a lot of variable that comes in play for Biotech, and there is a lot of uncertainty...and invivo studies are sort of pointless (at this stage, this is 200% given to be positive) as the company needs to go through multiple trial phases to provide it invivo concept...
I always said I will look to jump in, its that I think there will be a better time so I will wait.......That's why my sentiment never said sell or hold...I said "None" coz the above is something I apply..doesn't necessarily means its true and works every time.....
NYR Price at posting:
21.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)